Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03YRO
|
|||
| Former ID |
DNC011970
|
|||
| Drug Name |
(4S,5R)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine
|
|||
| Synonyms |
CHEMBL322085; (4S,5R)-4,5-Dipropyl-oxazolidin-(2Z)-ylideneamine; BDBM50138197
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H18N2O
|
|||
| Canonical SMILES |
CCCC1C(OC(=N1)N)CCC
|
|||
| InChI |
1S/C9H18N2O/c1-3-5-7-8(6-4-2)12-9(10)11-7/h7-8H,3-6H2,1-2H3,(H2,10,11)/t7-,8+/m0/s1
|
|||
| InChIKey |
LRHNWJTUXJXJRP-JGVFFNPUSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nitric-oxide synthase inducible (NOS2) | Target Info | Inhibitor | [1] |
| BioCyc | Citrulline-nitric oxide cycle | |||
| KEGG Pathway | Arginine biosynthesis | |||
| Arginine and proline metabolism | ||||
| Metabolic pathways | ||||
| Calcium signaling pathway | ||||
| HIF-1 signaling pathway | ||||
| Peroxisome | ||||
| Salmonella infection | ||||
| Pertussis | ||||
| Leishmaniasis | ||||
| Chagas disease (American trypanosomiasis) | ||||
| Toxoplasmosis | ||||
| Amoebiasis | ||||
| Tuberculosis | ||||
| Pathways in cancer | ||||
| Small cell lung cancer | ||||
| NetPath Pathway | IL1 Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathway Interaction Database | IL12-mediated signaling events | |||
| Alpha9 beta1 integrin signaling events | ||||
| ATF-2 transcription factor network | ||||
| IL23-mediated signaling events | ||||
| Signaling mediated by p38-alpha and p38-beta | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | ROS production in response to bacteria | |||
| Nitric oxide stimulates guanylate cyclase | ||||
| WikiPathways | Type II interferon signaling (IFNG) | |||
| Spinal Cord Injury | ||||
| AGE/RAGE pathway | ||||
| Effects of Nitric Oxide | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | 4,5-Disubstituted-1,3-oxazolidin-2-imine derivatives: a new class of orally bioavailable nitric oxide synthase inhibitor. Bioorg Med Chem Lett. 2004 Jan 19;14(2):313-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.